Kristine M Erlandson1, Melissa P Wilson2, Samantha MaWhinney2, Eric Rapaport1, Jay Liu1, Cara C Wilson1, Jeremy T Rahkola1, Edward N Janoff1,3, Todd T Brown4, Thomas B Campbell1, Catherine M Jankowski5. 1. Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 2. School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 3. Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado, USA. 4. Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA. 5. College of Nursing, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract
BACKGROUND: We investigated whether higher-intensity exercise provided greater decrease in markers of inflammation, and whether responses differed by HIV serostatus. METHODS: People with HIV (PWH; n = 32) and controls (n = 37) aged 50-75 years completed 12 weeks moderate-intensity exercise, then were randomized to moderate- or high-intensity exercise for 12 additional weeks (n = 27 and 29, respectively). Inflammation biomarkers were measured at 0, 12, 24 weeks. Mixed and multiple regression models were adjusted for baseline inflammation, age, and body mass index. RESULTS: Baseline tumor necrosis factor-α (TNF-α), soluble TNF receptor 2 (sTNFR2), and soluble CD14 (sCD14) were significantly higher among PWH than controls (P < .04). From week 0-12, changes in interleukin-6 (IL-6), TNF-α, and sTNFR1 were not significantly different by HIV serostatus. We found no significant interaction between HIV serostatus/exercise intensity on week 12-24 changes in IL-6, TNF-α, and sTNFR1. Among high-intensity exercisers, PWH and controls had significant increases in sCD14 (P ≤ .003), controls significant increases in IL-10 (P = .01), and PWH nonsignificant decrease in highly sensitive C-reactive protein (P = .07). Other markers were not significantly different by serostatus or intensity. CONCLUSIONS: Moderate and high-intensity exercise elicited similar effects on inflammation among PWH and controls, with additional beneficial effects seen among high-intensity exercisers. Increase in sCD14 and attenuated IL-10 increase (PWH only) merit further study. CLINICAL TRIALS REGISTRATION: NCT02404792.
BACKGROUND: We investigated whether higher-intensity exercise provided greater decrease in markers of inflammation, and whether responses differed by HIV serostatus. METHODS: People with HIV (PWH; n = 32) and controls (n = 37) aged 50-75 years completed 12 weeks moderate-intensity exercise, then were randomized to moderate- or high-intensity exercise for 12 additional weeks (n = 27 and 29, respectively). Inflammation biomarkers were measured at 0, 12, 24 weeks. Mixed and multiple regression models were adjusted for baseline inflammation, age, and body mass index. RESULTS: Baseline tumor necrosis factor-α (TNF-α), soluble TNF receptor 2 (sTNFR2), and soluble CD14 (sCD14) were significantly higher among PWH than controls (P < .04). From week 0-12, changes in interleukin-6 (IL-6), TNF-α, and sTNFR1 were not significantly different by HIV serostatus. We found no significant interaction between HIV serostatus/exercise intensity on week 12-24 changes in IL-6, TNF-α, and sTNFR1. Among high-intensity exercisers, PWH and controls had significant increases in sCD14 (P ≤ .003), controls significant increases in IL-10 (P = .01), and PWH nonsignificant decrease in highly sensitive C-reactive protein (P = .07). Other markers were not significantly different by serostatus or intensity. CONCLUSIONS: Moderate and high-intensity exercise elicited similar effects on inflammation among PWH and controls, with additional beneficial effects seen among high-intensity exercisers. Increase in sCD14 and attenuated IL-10 increase (PWH only) merit further study. CLINICAL TRIALS REGISTRATION: NCT02404792.
Authors: Jessica L Montoya; Catherine M Jankowski; Kelly K O'Brien; Allison R Webel; Krisann K Oursler; Brook L Henry; David J Moore; Kristine M Erlandson Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Meredith Greene; Kenneth Covinsky; Jacquie Astemborski; Damani A Piggott; Todd Brown; Sean Leng; Noya Galai; Shruti H Mehta; Jack Guralnik; Kushang V Patel; Gregory D Kirk Journal: AIDS Date: 2014-11-28 Impact factor: 4.177
Authors: Kristine M Erlandson; Jennifer A Schrack; Catherine M Jankowski; Todd T Brown; Thomas B Campbell Journal: Curr HIV/AIDS Rep Date: 2014-09 Impact factor: 5.071
Authors: Kim van Wijck; Kaatje Lenaerts; Luc J C van Loon; Wilbert H M Peters; Wim A Buurman; Cornelis H C Dejong Journal: PLoS One Date: 2011-07-21 Impact factor: 3.240
Authors: Catherine M Jankowski; Samantha Mawhinney; Melissa P Wilson; Thomas B Campbell; Wendy M Kohrt; Robert S Schwartz; Todd T Brown; Kristine M Erlandson Journal: J Acquir Immune Defic Syndr Date: 2020-11-01 Impact factor: 3.771
Authors: Janet P Tate; Amy C Justice; Michael D Hughes; Fabrice Bonnet; Peter Reiss; Amanda Mocroft; Jacob Nattermann; Fiona C Lampe; Heiner C Bucher; Timothy R Sterling; Heidi M Crane; Mari M Kitahata; Margaret May; Jonathan A C Sterne Journal: AIDS Date: 2013-02-20 Impact factor: 4.177